- •Preface to the Second Edition
- •Contents
- •List of Abbreviations
- •1: Epidemiology of AMD
- •Core Messages
- •1.1 Introduction
- •1.3 Frequency
- •1.3.1 Prevalence
- •1.3.2 Incidence
- •1.4 Natural Course
- •1.5 Genetic Factors
- •1.5.1 The Complement Pathway Genes
- •1.5.1.1 Complement Factor H (CFH)
- •1.5.1.3 Complement Component 3 (C3)
- •1.5.1.4 Complement Factor I (CFI)
- •1.5.2 The ARMS2 (10q26) Locus
- •1.5.3.1 Apolipoprotein E (APOE)
- •1.5.4 Candidate Gene Association Studies
- •1.6 Environmental Factors
- •1.6.1 Smoking
- •1.6.2 Antioxidants
- •1.6.3 Body Mass Index (BMI)
- •1.6.4 Hypertension
- •1.6.5 Cataract Surgery
- •1.7 Interaction Between Risk Determinants
- •1.7.1 Combined Effects of CFH Y402H and Other Genetic and/or Environmental Factors
- •1.7.2 Combined Effects of 10q26 SNPs and Other Genetic and/or Environmental Factors
- •1.7.4 Combined Effects of the APOE Gene and Other Genetic and/or Environmental Factors
- •References
- •2: Genetics
- •Core Messages
- •2.1 Introduction
- •2.2 Identifying Risk Factors of a Common Disease
- •2.3 Early Findings
- •2.4.1 Functional Implications
- •2.5.1 Functional Implications
- •2.7 Prospects of Genetics in AMD Therapy and Prevention
- •Summary for the Clinician
- •References
- •Core Messages
- •3.1 Introduction
- •3.2 Cause and Consequences of Ageing
- •3.3 Clinical Changes Associated with Retinal Ageing
- •3.4 Ageing of the Neural Retina
- •3.5 Ageing of the RPE
- •3.5.1 Changes in RPE Cell Density
- •3.5.2 Subcellular Changes in the RPE
- •3.5.3 Accumulation of Lipofuscin
- •3.5.4 Melanosomes and Pigment Complexes
- •3.5.7 Antioxidant Capacity of the RPE
- •3.6 Ageing of Bruch’s Membrane
- •3.7 The Association Between Ageing and AMD
- •Summary for the Clinician
- •References
- •Core Messages
- •4.1 Introduction
- •4.2 The Complement System
- •4.3 Evidence for Involvement of the Complement System in AMD Pathogenesis
- •4.4.2 Complement Gene Variants and AMD Subtypes
- •4.4.3 Complement Gene Variants and Progression of AMD
- •4.4.5 Variations of Complement Genes and Response to Treatment: Pharmacogenetics
- •4.5 Emerging Pharmacological Intervention Targeting Complement Dysregulation
- •Conclusions
- •Summary for the Clinician
- •References
- •5: Histopathology
- •Core Messages
- •5.1 Retinal Pigment Epithelium
- •5.1.1 Structure and Function of the Retinal Pigment Epithelium
- •5.1.3 Deposits in the RPE
- •5.2 Bruch’s Membrane
- •5.2.1 Structure of Bruch’s Membrane
- •5.2.3 Deposits in Bruch’s Membrane, Drusen
- •5.3 Choroidal Neovascularization
- •5.4 Detachment of the Retinal Pigment Epithelium
- •5.5 Geographic Atrophy of the RPE
- •Summary for the Clinician
- •References
- •6: Early AMD
- •Core Messages
- •6.1 Introduction
- •6.2 Drusen
- •6.2.3 Fluorescence Angiography and Optical Coherence Tomography
- •6.3 Focal Hypopigmentation and Hyperpigmentation of the Retinal Pigment Epithelium
- •6.4 Abnormal Choroidal Perfusion
- •Summary for the Clinician
- •References
- •Core Messages
- •7.1 Introduction
- •7.2.1 Decreased Visual Acuity
- •7.2.2 Visual Distortion
- •7.2.3 Visual Field Defects
- •7.2.4 Miscellaneous Symptoms
- •7.3 Signs of Choroidal Neovascularization
- •7.3.1 Hemorrhage
- •7.3.2 Macular Edema and Subretinal Fluid
- •7.3.3 Retinal Pigment Epithelial Detachment
- •7.3.4 Miscellaneous Signs
- •7.4 Common Testing Modalities to Diagnose Choroidal Neovascularization
- •7.4.1 Fluorescein Angiography
- •7.4.2 Indocyanine Green Angiography
- •7.4.4 Optical Coherence Tomography
- •Summary for the Clinician
- •References
- •8: Geographic Atrophy
- •Core Messages
- •8.1 Introduction
- •8.3 Histology and Pathogenesis of Geographic Atrophy
- •8.5 Spectral Domain Optical Coherence Tomography in Geographic Atrophy
- •8.7 Risk Factors
- •8.7.1 Genetic Factors
- •8.7.2 Systemic Risk Factors
- •8.7.3 Ocular Risk Factors
- •8.8 Development of CNV in Eyes with GA
- •8.9 Visual Function in GA Patients
- •8.9.1 Measurement of Visual Acuity
- •8.9.2 Contrast Sensitivity
- •8.9.3 Reading Speed
- •8.9.4 Fundus Perimetry
- •8.10 Perspectives for Therapeutic Interventions
- •8.10.2 Complement Inhibition
- •8.10.3 Neuroprotection
- •8.10.4 Alleviation of Oxidative Stress
- •8.10.5 Serotonin-1A-Agonist
- •8.10.6 Perspective
- •Summary for the Clinician
- •References
- •9: Fundus Imaging of AMD
- •Core Messages
- •9.1 Introduction
- •9.2 Color Photography
- •9.3 Monochromatic Photography
- •9.5 Optical Coherence Tomography
- •9.5.2 Coherence Length
- •9.5.3 Time Domain Optical Coherence Tomography
- •9.5.4 Frequency Domain Optical Coherence Tomography
- •9.5.5 Increasing Depth of Imaging
- •9.5.6 General Optical Coherence Tomographic Imaging Characteristics of the Macular Region
- •9.6 Fundus Angiography
- •9.6.1 Fluorescein Dye Characteristics
- •9.6.2 Indocyanine Green Dye Characteristics
- •9.6.3 Cameras Used in Fluorescence Angiography
- •9.6.4 Patient Consent and Instruction
- •9.6.5 Fluorescein Injection
- •9.6.6 Fluorescein Technique
- •9.6.7 Indocyanine Green Technique
- •9.7 Fluorescein Angiographic Interpretation
- •9.7.1 Filling Sequence
- •9.7.2 The Macula
- •9.8 Deviations from Normal Angiographic Appearance
- •9.10.1 Drusen
- •9.12 Neovascular AMD
- •9.13 Retinal Pigment Epithelial Detachments
- •9.14 Retinal Vascular Contribution to the Exudative Process
- •9.15 Follow-up
- •9.15.1 Thermal Laser
- •9.15.2 Photodynamic Therapy
- •9.15.3 Anti-VEGF Therapy
- •Summary for the Clinician
- •References
- •10: Optical Coherence Tomography
- •10.1 Introduction
- •Core Messages
- •10.4 OCT in Geographic Atrophy
- •10.5 OCT in Exudative AMD
- •Summary for Clinician
- •References
- •11: Microperimetry
- •Core Messages
- •11.1 Introduction
- •11.2.1 From Manual to Automatic Microperimetry
- •11.2.2 Automatic Microperimetry
- •11.2.3 Microperimetry: The Examination
- •11.2.4 Microperimetry: Test Evaluation
- •11.2.5 Other Microperimeter
- •11.3 Microperimetry in AMD
- •11.3.1 Early AMD
- •11.3.2 Geographic Atrophy
- •11.3.3 Neovascular AMD
- •11.3.4 Neovascular AMD: Treatment
- •Summary for the Clinician
- •References
- •Core Messages
- •12.1 Introduction
- •12.2 Antioxidants and Zinc
- •12.3 Beta-Carotene
- •12.4 Macular Xanthophylls
- •12.6 Vitamin E
- •12.7 Vitamin C
- •12.8 Zinc
- •12.10 AREDS2
- •Summary for the Clinician
- •References
- •Core Messages
- •13.1 Introduction
- •13.2 Basic Principles
- •13.2.1 Clinical Background
- •13.2.2 Laser Photocoagulation
- •13.2.3 Photodynamic Therapy
- •13.3 Treatment Procedures
- •13.3.1 Laser Photocoagulation
- •13.3.2 Photodynamic Therapy
- •13.4 Study Results
- •13.4.1 Laser Photocoagulation
- •13.4.1.1 Extrafoveal CNV
- •13.4.1.2 Subfoveal CNV
- •13.4.1.3 Meta-analysis
- •13.4.2 Photodynamic Therapy
- •13.4.2.1 Predominantly Classic
- •13.4.2.2 Occult with No Classic Neovascularization
- •13.4.2.3 Minimally Classic
- •13.5 Safety and Adverse Events
- •13.5.1 Laser Photocoagulation
- •13.5.2 Photodynamic Therapy
- •13.6 Variations
- •13.6.1 Laser Photocoagulation: Different Wavelengths
- •13.6.2 Photodynamic Therapy
- •13.6.3 Combination Treatments
- •13.7 Present Guidelines
- •13.7.1 Laser Photocoagulation
- •13.7.2 Photodynamic Therapy
- •13.8 Perspectives
- •Summary for the Clinician
- •References
- •Core Messages
- •14.1 Introduction
- •14.2 Vascular Endothelial Growth Factor (VEGF)
- •14.3 Targets Within the VEGF Pathway
- •14.3.1 Sequestration of Released VEGF
- •14.3.2 Inhibition of VEGF and VEGF Receptor Synthesis by Small Interfering RNA (siRNA)
- •14.3.3 Inhibition of the Intracellular Signal Cascade
- •14.3.4 Natural VEGF Inhibitors
- •14.4 New Methods of Drug Delivery
- •14.5 Combined Strategies
- •Summary for the Clinician
- •References
- •Core Messages
- •15.1 Introduction
- •15.1.1 Anti-VEGF Therapies for NV-AMD
- •15.2.1 How Should Neovascular AMD be Diagnosed?
- •15.2.4.1 Results with Continuous Monthly Treatment
- •15.2.4.2 How Should Treatment be Started?
- •15.2.4.3 What Flexible Approaches Are Reported?
- •Fixed Quarterly Injection Studies
- •Flexible Dosing Regimens: Two Approaches
- •Flexible Dosing Regimens: ‘As Needed’ Approach
- •Flexible Dosing Regimens: ‘Treat-and-Extend’ Approach
- •Summary for the Clinician
- •References
- •Core Messages
- •16.1 Introduction
- •16.3 Current Limitation of Therapy in the Treatment of Exudative AMD
- •16.4 Rationale for Combination Therapy in the Treatment of Exudative AMD
- •16.5 Clinical Data Examining Combination Therapy for Exudative AMD
- •16.5.3 Triple Therapy for Exudative AMD
- •16.5.4 Combination Therapy with Radiation
- •Summary for the Clinician
- •References
- •Core Messages
- •17.1 Introduction
- •17.2 Current Treatment Options for Dry AMD
- •17.3 Targeting the Cause of AMD
- •17.4 Preclinical and Phase I Drugs in Development for Dry AMD
- •17.4.1 Clinical Trial Endpoints in Dry AMD
- •Trimetazidine
- •17.4.2.2 Neuroprotection
- •Ciliary Neurotrophic Factor (CNTF/NT-501)
- •AL-8309B (Tandospirone)
- •Brimonidine Tartrate Intravitreal Implant
- •17.4.2.3 Visual Cycle Modulators
- •Fenretinide
- •17.4.2.4 Other
- •17.4.3 Drugs to Prevent Injury from Oxidative Stress and Micronutrient Depletion
- •17.4.4.1 Complement Inhibition at C3
- •17.4.4.2 Complement Inhibition at C5
- •Eculizumab
- •17.4.4.3 Complement Inhibition of Factor D
- •FCFD4514S
- •Iluvien
- •Glatiramer Acetate (Copaxone)
- •17.5 Summary
- •Summary for the Clinician
- •References
- •18: Surgical Therapy
- •Core Messages
- •18.1 Maculoplasty
- •18.2 Macular Translocation
- •18.3 Single Cell Suspensions
- •18.5 Indications for Surgery
- •18.5.1 Non-responder
- •18.5.2 Pigment Epithelium Rupture
- •18.5.3 Massive Submacular Bleeding
- •18.5.5 Macula Dystrophies
- •Summary for the Clinician
- •References
- •19: Reading with AMD
- •Core Messages
- •19.1 Introduction
- •19.2 Physiological Principles
- •19.3 Reading with a Central Scotoma
- •19.3.1.2 The Reading Visual Field Related to the Fundus (Fig. 19.4b)
- •19.3.1.3 The Reading Visual Field Related to the Text (Fig. 19.4c)
- •19.3.1.4 Eccentric Fixation Related to the Globe (Fig. 19.5)
- •19.3.3 Examination of Fixation Behaviour
- •19.3.4 Motor Aspects
- •19.4 Methods to Examine Reading Ability
- •19.5 Rehabilitation Approaches to Improve Reading Ability
- •Summary for the Clinician
- •References
- •20: Low Vision Aids in AMD
- •Core Messages
- •20.2 Effects of Visual Impairment in AMD
- •20.5 Optical Magnifying Visual Aids for Distance
- •20.5.1 Aids for Watching Television
- •20.8 Electronic Reading Instruments
- •20.9 Additional Aids
- •20.10 Noteworthy Details for the Provision of Low Vision Aids
- •20.11 Basic Information on Prescription
- •Summary for the Clinician
- •References
- •Index
5 Histopathology |
|
|
|
91 |
|||||
|
|
|
|
|
|
|
|
|
|
RPE |
|
RPE |
|
|
RPE |
||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Lipofuscin |
|
|||
|
Lipofuscin |
|
Matrix Enzymes |
||||||
VEGF |
|
VEGF |
|
|
VEGF |
|
|
||
|
|
||||||||
|
|||||||||
BM |
|
|
|
Lipids |
NV |
|
|
|
Young |
Old |
Chorioidal |
Neovascularization |
Fig. 5.14 Schematic diagram of the pathogenesis of CNV. Increasing lipid deposits within Bruch’s membrane diminish the concentration of growth factors (VEGF) essential for the maintenance of a normal choriocapillaris structure, regression of capillaries ensuing relative hypoxia of the retinal pigment epithelium,
leading to an increased production of growth factors and matrix enzymes, provoking the ingrowth of choroidal capillaries (NV). VEGF vascular endothelial growth factor, BM Bruch’s membrane, NV neovascularization
permeability of Bruch’s membrane for these growth factors leads to a regression of the choroidal capillaries. Hypoxia and lipofuscin-dependent changes in the metabolism of RPE cells follow [102, 103] and can cause enhanced production of growth factors like vascular endothelial growth factor (VEGF). In combination with the altered synthesis and degradation of matrix molecules, this increased supply of VEGF gives rise to an immigration of newly formed choroidal capillaries (Fig. 5.14).
In CNV there are many open questions left. For instance, it is unclear why the preferential manifestation of CNV is in the macular area. Only very rarely are choroidal neovascularizations in the retinal periphery. The vessels mostly develop at the posterior pole of the eye and grow towords the fovea [51]. Higher concentrations of growth factors in the central retina or a preferred destruction of central RPE cells are believed to cause this phenomenon [104]. The density of the photoreceptor cells is highest in the retinal center, thus leading to a high load of metabolic waste in this part of the retina. Correspondingly, the age-related deposition of granules loaded with lipofuscin in the RPE cells is maximal. In addition, the thickening of Bruch’s membrane underlying the macular part is most explicit in this area [7, 94], and drusen are found primarily at the posterior fundus pole [6, 69]. An age-related calcification increase of the fibers in the elastic layer of Bruch’s membrane is observed. Especially in the macular part, the calcified fibers may break which may promote neovascularization [86]. Age-related retinal changes and alterations in the RPE are most prominent in the area of the underlying macula. This may contribute to the preferential occurrence of CNV in that delicate area.
5.4Detachment of the Retinal Pigment Epithelium
During RPE detachment (PED), the complete RPE cell layer with the connected photoreceptor cells and the neural retina is detached from the inner collagenous layer of Bruch’s membrane. The resulting cavity is filled with serous fluid. The detection of a PED is often delayed because loss of vision occurs only at the late stage.
PED is observed in different retinal diseases. The resulting accumulation of fluid in the lumen under the RPE has been described to occur clinically very early when accompanying AMD [77, 105]. About 10% of all patients with exudative AMD suffer from PED [106].
Histologically, the detachment is between the RPE basement membrane and inner collagenous layer of Bruch’s membrane (Fig. 5.15). CNV (see Sect. 5.3) is often associated with the detachment and a disciform scar may form with progressing disease. After a PED apoptosis of RPE cells and cell death of photoreceptor cells may occur, leading to the development of an atrophic area [107–109].
Bruch’s membrane plays a key role in PED. In addition to its thickening by diffuse or localized deposits - as hallmarks of early AMD - its pentalaminar composition becomes indistinct. This is accompanied by an increasing deposition of membranous as well as high-density particles. Bruch’s membrane undergoes structural changes that alter its biochemical composition and hence its physical and physiological qualities. In Sect. 5.2.2, the involved processes of collagen cross-linking, calcification, deposition of lipids
92 |
A. Lommatzsch et al. |
|
|
and alterations of protein ingredients are described in detail. These processes also occur during the normal ageing process of Bruch’s membrane, however, preferentially under the macula and are found more often in predisposed people.
There is experimental evidence that PED may be caused by its activity as a fluid pump. Due to the agerelated increased lipid deposition into Bruch’s membrane it is postulated to become more and more of a hydrophobic barrier whilst the amount of fluid to be
Fig. 5.15 Pigment epithelial detachment in histology stained with oil red O (magnification 250-fold) revealing cleavage of the inner collagenous layer of Bruch’s membrane and deposition of serous lipid-containing fluid
transported through the RPE stays consistent. This situation is thought to lead to serous PED [100].
In patients with PED, an irregular dispersion of hydrophilic sodium fluorescein in fluorescence angiography can be detected. This may be caused by irregularly deposited lipophilic material in Bruch’s membrane. Drusen with a low fatty acid content are very well visible with this technique, while the specimens rich in lipids cannot be detected [42]. This may provide an explanation for the irregular dispersion of the fluorescent dye. Furthermore, it is well known that protruding hyperfluorescent and hydrophobic soft drusen are risk factors for a PED [60, 110].
Serous PED may be associated with a CNV. In this situation irregular blood vessels grow through Bruch’s membrane and form a membrane composed of fibrovascular tissue (Fig. 5.16). The PED is clearly illustrated and identified in optical coherence tomography as well as in fluorescence angiography (Fig. 5.17).
The increasing lipid content in an ageing Bruch’s membrane reduces the permeability to water-soluble substances. This impedes the exchange of material and fluid between the RPE and choroid, enhancing the barrier function of Bruch’s membrane. Reduced permeability to water passing Bruch’s membrane with increasing age and lipid content was confirmed by several studies
a |
b |
Fig. 5.16 Vascularized pigment epithelial detachment. (a) Fluorescein angiography: large hypofluorescence with hyperfluorescent occult CNV at the nasal edge. (b) Histological section of the same lesion: The RPE appears to be detached together
with basally associated diffuse deposits (open arrow) from a clearly neovascularized (arrow) fibrovascular tissue. Within the subretinal space (asterisk) increasing collagen deposits after serous exudation indicate the healing process
5 Histopathology |
|
93 |
|
|
|
|
|
Fig 5.17 Pigment epithelial |
a |
b |
|
detachment in optical |
|||
|
|
||
coherence tomography (a) |
|
|
|
completely and (b) sectional |
|
|
|
plane shown in (a) as green |
|
|
|
arrow |
|
|
[38, 111]. They revealed a diminished number of pores in Bruch’s membrane and in persons aged 50 years or more. Further, there was a linear relation between a high lipid content and a strong flow-through resistance. In hampering the exchange of material passing Bruch’s membrane, the inner collagenous layer was shown to play the most important role [40].
Other analyses showed a hindered transport of amino acids through the complex of Bruch’s membrane and choroid with increasing age, which may point to a bad nutritional supply in general [112]. With increasing age retinal maintenance is further hampered by a reduced diameter of choroidal capillaries in combination with a lower density of the capillary mesh [56]. The diffusion and exchange of nutrients and metabolites between choroid and RPE cells is essential for a healthy retina [113]. A decline will result in an accelerated retinal undersupply.
So-called integrins - adhesion proteins on the RPE cells - play an essential role in the attachment of the RPE cell layer with its basement membrane to the inner collagenous layer of Bruch’s membrane. In addition to age-related alterations in the expression of different integrin-subunits one knows from blockage experiments that not only the extent of expression but also the correct aligment of the integrin subunits are crucial for adhesion strength [114, 115]. Therefore, an altered integrin expression pattern and rate may be an early sign of PED. A decreased expression and abnormal alignment of integrin subunits may also hamper
reattachment when the fluid under the detachment is absorbed. In addition, the amount of laminin in the retina changes with age; laminin 5 being particularly important for RPE adhesion [117].
The adhesion proteins on the surface of RPE cells bind to extracellular matrix components of Bruch’s membrane. Modification of these components by cross-linked collagen and oxidative damage is another risk factor for PED.
At First it was assumed that serous fluid stems from leaking choroid capillaries or is secreted by abnormal retinal blood vessels growth (Fig. 5.18a) [77, 118]. A directional flow of fluid from the vitreous through the retina to the choroid is physiologically inherent by the net transport of ions passing the RPE and its barrier function [119, 120]. If the PED is accompanied by a CNV or a retinal angiomatous proliferation associated with a penetration of the RPE, these leaking vessels can contribute to the accumulation of fluid. As a PED is not always associated with a CNV, there also have to be other fluid sources [121]. Experiments with isolated RPE layers from dogs showed that even a strong hydrostatic pressure gradient does not change the fluid flow through the RPE [122]. This indicates that the pump activity of the RPE itself may be strong enough to part this cell layer from the underlying Bruch’s membrane, which becomes more and more brittle and hydrophobic with increasing age (Fig. 5.18b) [54]. It can thus be assumed that both, leakage from choroidal neovascular vessels as well as a strong pump activity of the RPE together
